small molecule screening assay (BioFocus DPI)
90
Structured Review
BioFocus DPI
small molecule screening assay
Small Molecule Screening Assay, supplied by BioFocus DPI, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/throughput+screening/high+throughput+screening/pmc04871731-445-15-19
Average 90 stars, based on 1 article reviews
Small Molecule Screening Assay, supplied by BioFocus DPI, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/throughput+screening/high+throughput+screening/pmc04871731-445-15-19
Average 90 stars, based on 1 article reviews
small molecule screening assay - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: In Brief Article Snippet: On February 10, pharmaceutical giant Johnson & Johnson (J&J; New Brunswick, NJ) announced the purchase of biopharmaceutical firm Scios (Sunnyvale, CA) for $2.4 billion in an all-stock transaction.. Scios shareholders will receive $45 per share, a 30% premium on Scios’ February 7 share price, which rose 26% to $43.92 on the news.. J&J gets Scios’ Natrecor, a recombinant human B-type natriuretic peptide for congestive heart failure with annual sales expected to reach $160–170 million in 2003. Article Title: Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-D-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC) Article Snippet: Herein we report the high-throughput screen (HTS) of 201,368 compounds from the Article Title: Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding Article Snippet: We thank Article Title: CONCENTRATES Article Snippet: Three biotech firms announced restructuring plans and staff cuts last week.. QLT, which specializes in eye disease therapy, announced a plan to halt other drug development programs that could amount to a 46% reduction of its staff of 474.. Half the jobs will be eliminated in January; the rest may be cut through subsequent divestitures, according to Acting CEO Robert Butchofsky. Article Title: Summary of Recent Deal Activity Article Snippet: Abbott, Celera Genomics R&D agreement Two antigen targets discovered by Celera Genomics have been selected for further investigation by Abbott for therapeutic development.. These are the first targets to be selected for advancement in the strategic collaboration established in 2004.. Under the terms of the agreement, a number of protein antigens identified and validated by Celera Genomics are being screened by Abbott. Screening Assay:Article Title: A small molecule mitigates hearing loss in a mouse model of Usher syndrome III Article Snippet: .. N.A.L. accommodated the small Control:Article Title: Screening assay for insecticides Article Snippet: .. Sample control group averages from |